… reported cost-effectiveness analyses in China that the afatinib … ) of cost-effective acceptance
of afatinib versus chemotherapy… The afatinib strategy was not accepted to be cost-effective …

… The purpose of this study was to evaluate the cost-effectiveness of the combined use of
afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine-cisplatin as the …

… , afatinib significantly prolonged PFS compared with gefitinib, with a numerical overall survival
(OS) trend in favor of afatinib … was undertaken to assess afatinib and gefitinib costs, with …

… Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a
first-… The objective of this study was to evaluate the cost-effectiveness of afatinib versus …

… Afatinib also had 100% probability to be cost-effective at a … that afatinib was a cost-effective
option. However, we found that afatinib might be a dominant strategy due to the lower cost …

… Afatinib has recently been directly compared with erlotinib, an EGFR, as second-line …
Citation16 The aim of the present analysis was to determine the cost-effectiveness of afatinib versus …

… , the use of real-world data to directly compare the effectiveness and cost effectiveness of …
was to assess the comparative cost effectiveness of three EGFR-TKIs, afatinib, erlotinib, and …

… The total cost of afatinib versus erlotinib was 12,364 versus 9510 EUR, … for afatinib
versus erlotinib. Their conclusion was consistent with our finding that afatinib was a cost-effective …

… The result of the study revealed that afatinib as a first-line treatment had a cost effective
advantage over gefitinib in all three groups, especially the del19 subgroup. However, the clinical …

… blocker afatinib and the … cost and health outcomes of afatinib and gefitinib in this setting.
Methods: A partitioned survival model was designed to assess the cost-effectiveness of afatinib …